New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer


  • Study

    Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02)
    HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast cancer
    Trastuzumab-deruxdeca (n=406) vs. SOC (n=202)




  • Efficacy

    mPFS: 17.8 vs 6.9 mos, p<0.0001
    12 months PFS: 62% vs. 27%
    24 months PFS: 42% vs 13%
    mOS: 39.2 vs. 26.5 mos, p=0021
    12 months OS: 89.4% vs.74.7%
    24 months OS: 65.9% vs.54.3%



  • Safety

    Grade≥3 AEs: Neutropenia (11% vs 2%), Anemia (8% vs. 3%), nausea (7% vs 3%), palmar-plantar erythrodysesthesia (1% vs 10%), diarrhea (3% vs. 7%)



  • Lancet Oncol, 20 APR, 2023

    Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomized, open-label, multicentre, phase 3 trial

    http://doi.org/10.1016/S0140-6736(23)00725-0

    Reviewed by Elvin Chalabiyev, MD on May 20, 2023